Healthcare Industry News: Inflammatory Bowel Disease
News Release - September 26, 2016
MOTUS GI(TM) Receives FDA Clearance to Market the Pure-Vu(TM) System for Cleansing Poorly Prepared Colons During ColonoscopyTIRAT CARMEL, ISRAEL--(Healthcare Sales & Marketing Network) - MOTUS GI, a medical device company dedicated to improving colonoscopy outcomes and experiences, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Pure-Vu System. The Pure-Vu System works with standard colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure, reducing the sole dependency on pre-procedural prep regimes to reliably and consistently obtain clear visualization of the colon wall.
"Colonoscopy prep can be unpleasant for patients and can impact compliance to the prescribed prep regimens," said Dr. Steven Edmundowicz, medical director of the University of Colorado Digestive Health Center. "A significant percentage of all patients undergoing a colonoscopy are inadequately prepped, which leads to issues in obtaining clear visualization and an accurate diagnosis for the patient. Poorly prepped colons can lead to prolonged procedure times, missed adenomas and cancers, repeat exams and reduced patient satisfaction."
Pure-Vu uses a mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high-quality examination -- even when the patient did not complete a successful prep on his or her own. The Pure-Vu System consists of a disposable component and a workstation controller. The disposable fits over standard colonoscopes without interfering with the working channel, allowing the physician to intra-procedurally clean and then visualize, diagnose and, if necessary, treat the colon in a standard fashion.
"One of the greatest challenges with colonoscopies is that the procedure often has to be repeated earlier than recommended guidelines due to an inadequate preparation that can obstruct the visualization of polyps or other anomalies in the colon," said Mark Pomeranz, CEO of MOTUS GI. "With FDA clearance of Pure-Vu, we can now provide physicians with more flexibility in treating their patients, while addressing issues such as early repeat procedures, missed adenomas, reduced patient satisfaction and higher costs that are associated with poorly prepared colons. In the coming months we will move forward with our pilot commercial launch of the Pure-Vu System focusing on both the in-hospital and outpatient settings."
About Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S. with approximately 50,000 deaths and 140,000 new cases of CRC diagnosed each year. The lifetime risk of developing CRC is about 1 in 20 -- or 5%. Through the use of colonoscopies, however, CRC has become one of the most preventable cancers.
Colonoscopy is one of the most common medical procedures performed with 15 million procedures performed in the US annually. Approximately 55% percent of colonoscopies are conducted as the standard of care for detecting colorectal cancer (CRC), while the remaining 45% are focused on diagnosis and surveillance of patients with gastrointestinal issues such as bleeding, Inflammatory Bowel Disease and motility challenges.
About MOTUS GI
MOTUS GI is a medical technology company based in Tirat Carmel, Israel. Spun out of the NGT incubator in 2011 by Orchestra Medical Ventures, the company is focused on the development and commercialization of the Pure-Vu System to improve the colonoscopy experience for physicians, patients and payers by enhancing the quality and cost-effectiveness of the exam. The Pure-Vu System is indicated to connect to standard colonoscopes to perform intra-procedural cleaning of a poorly prepared colon, thereby reducing the sole dependency on a successful pre-procedural prep regimen to gain clear visualization of the colon mucosa. For more information, visit www.motusgi.com.
This press release contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: MOTUS GI
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.